Table I.
IC50 based on WST-1 viability assay following treatment with CDK4/6 PD-0332991, WEE1 G2 checkpoint kinase MK-1775 and poly-ADP-ribose-polymerase inhibitor BMN-673.
| A, PD-0332991 | |||
|---|---|---|---|
|
| |||
| IC50, µM | |||
|
|
|||
| Cell line | 24 h | 48 h | 72 h |
| SK-N-AS | 12.7a | 24.5a | 11.5a |
| SK-N-BE(2)-C | 19.8a | 0.1a | 0.1a |
| SK-N-DZ | 18.8a | 3.9 | 2.3 |
| SK-N-FI | 1532a | 26.4a | 34.9a |
| SK-N-SH | 5.0 | 2.3 | 2.1 |
|
| |||
| B, MK-1775 | |||
|
| |||
| IC50, µM | |||
|
|
|||
| Cell line | 24 h | 48 h | 72 h |
|
| |||
| SK-N-AS | 1.5 | 0.3 | 0.3 |
| SK-N-BE(2)-C | 1.3 | 1.0 | 1.0 |
| SK-N-DZ | 0.4 | 0.2 | 0.1 |
| SK-N-FI | 6.6 | 1.8 | 0.6 |
| SK-N-SH | 4.9 | 2.5 | 1.0 |
|
| |||
| C, BMN673 | |||
|
| |||
| IC50, µM | |||
|
|
|||
| Cell line | 24 h | 48 h | 72 h |
|
| |||
| SK-N-AS | 109.8a | 174.5a | 63.6 |
| SK-N-BE(2)-C | 152.1a | 20.4 | 7.1 |
| SK-N-DZ | 109.6a | 621.2a | 13.2 |
| SK-N-FI | 195.4a | - | - |
| SK-N-SH | 83.0 | 1.0 | 0.1 |
IC50 was determined from log concentrations effect curves in GraphPad Prism using non-linear regression analysis.
a
Extrapolated value outside the tested concentration range. IC50, half-maximal inhibitory concentration; -, not determined.